Company Profile
Amgen Inc. Stock Price, News & Analysis
- Ticker:
- AMGN
- Exchange:
- NASDAQ
- Sector:
- Generics, Biopharma, Oncology, Immunotherapy
- Location:
- Thousand Oaks, California
Stock performance
404.85 USD (-0.73%)
Close
Last updated: August 6, 2026
177B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, AMGN closed down 0.73% at $404.85. No new same-company headline was identified in the current news window.
Company overview
Business overview
Amgen develops, manufactures, and commercializes therapies across oncology, inflammation, bone health, cardiovascular disease, and rare disease. Marketed products such as Enbrel, Prolia, Repatha, Otezla, and Tepezza anchor the revenue base while the pipeline keeps catalysts in view.
Geographic Base and Sector Classification
Headquartered in Thousand Oaks, California and listed on NASDAQ, Amgen is a global biotechnology company with substantial U.S. and international revenue exposure. Its profile is shaped by scale, commercialization, and a broad therapeutic footprint.
Business Model Characteristics
Amgen uses commercial cash flow to fund R&D and business development across both mature and newer franchises. Investors tend to watch launch execution, regulatory events, and portfolio refresh rather than pure clinical-stage binary risk.
Position Within the Biotechnology Landscape
Amgen is one of the best-known large-cap biotech names and usually trades with less single-asset dependence than smaller peers. It still moves on pipeline, regulatory, and label milestones, but its diversified base makes the story more durable.
Future catalysts
Amgen’s near-term catalysts are TEPEZZA subcutaneous development, Repatha’s cardiovascular growth, and any MariTide update that could reset the obesity narrative. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
Recent news
- 01
FDA approves late-stage oncology treatment
Source: amgen.com
- 02
Management commentary keeps pipeline priorities in focus
Source: amgen.com
- 03
Investors watch oncology and cardiometabolic launch cadence
Source: newswire
- 04
Regulatory calendar keeps Amgen in the spotlight
Source: sec.gov
- 05
Pipeline updates reinforce the commercial-stage narrative
Source: conference
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Amgen Inc. (AMGN)?
Amgen Inc. (AMGN) most recently closed at 404.85 USD, a -0.73% move versus the previous session.
What is the market cap of Amgen Inc. (AMGN)?
Amgen Inc. currently has a market capitalization of 177B USD on BioPharmSignal.
What does Amgen Inc. do?
Amgen develops, manufactures, and commercializes therapies across oncology, inflammation, bone health, cardiovascular disease, and rare disease. Marketed products such as Enbrel, Prolia, Repatha, Otezla, and Tepezza anchor the revenue base while the pipeline keeps catalysts in view.
On which exchange is AMGN stock listed?
Amgen Inc. (AMGN) is associated with NASDAQ, Thousand Oaks, California, Generics, Biopharma, Oncology, Immunotherapy.
What is Amgen?
Amgen’s near-term catalysts are TEPEZZA subcutaneous development, Repatha’s cardiovascular growth, and any MariTide update that could reset the obesity narrative.
Which conditions is Amgen Inc. targeting with Amgen?
Amgen Inc. is associated with oncology, inflammatory disease, rare disease based on its company overview and current catalyst commentary.
How does Amgen Inc. describe recent progress with Amgen?
Amgen’s near-term catalysts are TEPEZZA subcutaneous development, Repatha’s cardiovascular growth, and any MariTide update that could reset the obesity narrative.
What is Marketed?
Marketed products such as Enbrel, Prolia, Repatha, Otezla, and Tepezza anchor the revenue base while the pipeline keeps catalysts in view.